| Study period | ||||
---|---|---|---|---|---|
Screening | Baseline | Follow-up | Post-trial | ||
Visit | Â | 1 | 2 | 3 | |
Time point | Â | Day 0 | Week 12 | Week 24 | Week 36 |
Enrollment | Â | Â | Â | Â | Â |
 Eligibility screening | X |  |  |  |  |
 Written informed consent |  | X |  |  |  |
 Randomization and allocation (after eligibility criteria met and written informed consent obtained) |  | X |  |  |  |
Interventions | Â | Â | Â | Â | Â |
 First stage: L. reuteri vs placebo |  |  | X |  |  |
 Second stage: L. reteri plus OXT spray vs placebo plus OXT spray |  |  |  | X |  |
Assessments | Â | Â | Â | Â | Â |
 Past medical history and medications | X |  |  |  |  |
 Surveys (ABC, SRS-2, GSI, and microbiome) |  | X | X | X |  |
 Labs (OXT and fecal microbiome) |  | X | X | X |  |
 Tests (emotion matching and eye-tracking) |  | X | X | X |  |
 Adverse events |  |  | X | X | X |